Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. - Wikidata - awgldk - TriplyDB

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

http://www.wikidata.org/entity/Q36182476

about

The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome β-cell replacement sources for type 1 diabetes: a focus on pancreatic ductal cells Recent advances in primary Sjogren's syndrome Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes Inducing and Administering Tregs to Treat Human Disease Promises and paradoxes of regulatory T cells in inflammatory bowel disease Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity Regulatory T-cell therapy in transplantation: moving to the clinic IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Immune therapy in type 1 diabetes mellitus Type 1 diabetes: translating mechanistic observations into effective clinical outcomes Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study Type 1 diabetes mellitus.Regulatory T cells in AKI.Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.AAV-mediated pancreatic overexpression of Igf1 counteracts progression to autoimmune diabetes in mice.Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2.IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells.Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.Treg vaccination in autoimmune type 1 diabetes.Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.Immune intervention for type 1 diabetes, 2013-2014 Immune therapy for treating type 1 diabetes: challenging existing paradigms.Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease.The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells.T cells in the control of organ-specific autoimmunity Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus Thinking bedside at the bench: the NOD mouse model of T1DM.Regulatory T cells in human and angiotensin II-induced mouse abdominal aortic aneurysms.Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD mice.

P2860

Q21131158-F73DD07B-4D05-40D2-BD90-3C2F930EEEF5 Q26740314-1BE34787-F885-4A2E-8CFF-336E20C16547 Q26747049-19748CFD-A838-4350-996C-23A4FC917DB4 Q26751244-B0CDA782-83F4-4E16-897E-CD1A0AA8E9F8 Q26770386-4CF3A8A9-ABDD-4CA5-8127-20E6A5C4301D Q26772723-47B4F9ED-6553-4EF7-B3F2-6BA20216F9EC Q26777557-612F1369-FE6B-4AF7-9854-946BE5D0BDDC Q26850621-089A8CD1-052F-4849-BC01-8DBB34A6E4A6 Q27008200-A00F07B9-8C87-457B-B271-6E746835D6B0 Q27025869-1CF89E18-2B93-4372-A6BE-93A5E657A783 Q27303126-DD6AEE24-7AAB-4BDA-925B-C9061CE1D1C3 Q28081034-B00ECBB2-4847-42C6-B994-CCCAF7C065D5 Q28282846-C0039FDB-E34E-4328-A02D-1F1CE795BF4F Q28287737-996CADE1-65C0-40CB-A13E-F84699801D34 Q28554636-857AD1E5-570C-43E5-941C-86B581A6540B Q28604189-74A0DA7A-82DE-4E9D-B238-81684352655A Q30235021-AD872D3A-A152-429E-96CF-F1292BD8F5B0 Q30409790-A15935D4-1AD1-463D-9B2F-2440E5C98E41 Q33744839-83F8FDD7-B961-42CB-B7F2-9AE99B75F4E2 Q33811204-75301989-6600-4849-8622-E1F48F71C721 Q33836234-D7B095AD-A1AB-440C-ACAA-1D1E9F812BE8 Q34318993-943EA44B-9F04-4214-9781-523CC8B48B20 Q34375578-2C5C5586-10C9-4E85-9645-5D773AE52687 Q34636874-7DE33ECD-B6B2-4949-998A-8539084FC4AB Q34651528-04F3341E-BEFA-4452-9283-7CEDF436366D Q34651540-FE7177FD-D9C9-44A3-AA24-57AB936FFE29 Q34901832-90F658EE-19D0-434D-B899-39DDFF30ED27 Q34957397-597B7C04-EFAC-47B2-A1E3-9CF494CF9890 Q34982489-B631373E-A1CD-49A3-8271-8F35796ED4A4 Q35098402-E51AB56C-A463-4F0C-AFF9-878233932F38 Q35242386-AFFCD92C-E54F-489A-86D8-A21A8E9D0485 Q35242428-7799FC1B-FA6C-40E0-9730-5354CB185225 Q35630698-29CE106A-E08E-4E82-96E4-3D61C0A6292E Q35635336-991329BC-BD4F-4E76-9ED6-7B619766E629 Q35836118-5E0CCCC1-8F01-446A-8EDE-C1365BCA62B2 Q35858597-475F878C-2424-4FB2-896C-C7C3211CD158 Q35911875-D88B48BD-5498-4D7D-9660-347337D4FC58 Q36027826-0E06DDC6-D2E6-4BF5-B105-BEEA77899DE1 Q36216535-18995854-A778-48EB-ADB8-748B858CE47D Q36327212-5DA95F17-0A93-4E68-ADDA-A41412ED9444

P2860

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

http://www.wikidata.org/entity/Q36182476

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Rapamycin/IL-2 combination the ...... ently impairs β-cell function.

@ast

Rapamycin/IL-2 combination the ...... ently impairs β-cell function.

@en

type

label

Rapamycin/IL-2 combination the ...... ently impairs β-cell function.

@ast

Rapamycin/IL-2 combination the ...... ently impairs β-cell function.

@en

prefLabel

Rapamycin/IL-2 combination the ...... ently impairs β-cell function.

@ast

Rapamycin/IL-2 combination the ...... ently impairs β-cell function.

@en

P1433

Q36182476-77361F41-AF17-46D9-926F-31A4394BB2E0

P1476

Q36182476-FBA1B7F8-CB93-4224-BE4A-C9CBE2525D95

P2093

Q36182476-09159814-0614-4289-A460-FB6F1846EA5C

Q36182476-109A21F7-F45B-43B7-97E8-AF2F5878F07F

Q36182476-2F3BAFF9-B24F-4378-8306-1EBEFC5FCF0F

Q36182476-3A6AE8D9-757F-46C4-BD44-D4A6956FF3C5

Q36182476-54C923A6-61C1-437A-BCCF-AC59F9677CE2

Q36182476-5DE39372-E677-4EBF-92F8-FEAE0EF0F4F2

Q36182476-61E58480-42A2-4EFB-B9FA-DE212CD5341B

Q36182476-6F35CB9E-1B01-49E9-8AB8-859540F7B77E

Q36182476-77059AC5-FBD3-4E00-986B-33922FDFD7DD

Q36182476-7E5148CC-6CB2-4A8F-9349-8BC8AC3D4082

P2860

Q36182476-04534FE5-7592-47FE-B7FF-7778A6DEAC09

Q36182476-049FA1D4-8B13-4042-9C6D-98072DE059B3

Q36182476-08AC592F-EDD9-4295-9995-8042011017B1

Q36182476-09330B80-ACF0-4F31-A6CD-A407CF0514A0

Q36182476-15D4ECDE-4686-4F21-9F1F-262E3D627BBA

Q36182476-17EBF9F3-06A8-4398-BB5F-3305BB644937

Q36182476-271A921D-B333-4E92-BF31-1C922D3D4254

Q36182476-28617515-88E8-46C9-B06D-BF55C6F7976D

Q36182476-36DBE1EA-FDC5-491E-8C17-805D6D80D87D

Q36182476-38DB8A41-5174-4AE0-B328-07EF7DABA7BF

P304

Q36182476-F19B8EA5-7AF5-4C91-8CB9-1C9187BA2064

P31

Q36182476-849BF0BD-221C-49A1-85B1-11831777F7AC

P356

Q36182476-BB991AAE-9E91-4A0D-9F28-438673706A53

P407

Q36182476-76407282-DDF1-41A5-8DF9-6E67A291ECDC

P433

Q36182476-5729BDF0-0AE1-4A34-A1BE-51D25C769A35

P478

Q36182476-D5573B32-AD67-42AA-AF77-A537993E0DE9

P50

Q36182476-7AE11C09-994A-4DD8-8251-916C7A7F806A

P577

Q36182476-B8BF012C-4284-4C04-B8F6-884DFF65BB32

P5875

Q36182476-F2F307D7-4A72-47BF-8A95-23C99D3ADC67

P698

Q36182476-3602B7F0-48CD-4F56-BCFA-829B88D2435A

P921

Q36182476-9311308B-A2DD-4564-9E45-33A7A0C5324D

Q36182476-9A618B19-BC71-429E-A938-42903F27EAF1

P932

Q36182476-E06BAE15-AB21-4917-B8F7-836469C363E0

P356

P1433

P1476

Rapamycin/IL-2 combination the ...... ently impairs β-cell function.

@en

P2093

Alex Rabinovitch

http://www.w3.org/2001/XMLSchema#string

Andrew Ahmann

http://www.w3.org/2001/XMLSchema#string

Carla J Greenbaum

http://www.w3.org/2001/XMLSchema#string

Deborah Phippard

http://www.w3.org/2001/XMLSchema#string

Diabetes TrialNet and the Immune Tolerance Network

http://www.w3.org/2001/XMLSchema#string

Jane H Buckner

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Bluestone

http://www.w3.org/2001/XMLSchema#string

Jennifer B Bollyky

http://www.w3.org/2001/XMLSchema#string

Karen D Boyle

http://www.w3.org/2001/XMLSchema#string

Laurence A Turka

http://www.w3.org/2001/XMLSchema#string

P2860

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction

Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes

Immunoregulatory functions of mTOR inhibition.

mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS.

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

The biology of interleukin-2.

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases

P304

2340-2348

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB12-0049

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227856521

http://www.w3.org/2001/XMLSchema#string

P698

22721971

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3425404

http://www.w3.org/2001/XMLSchema#string